PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrom… Read more
PaxMedica, Inc. Common Stock (PXMD) - Total Liabilities
Latest total liabilities as of September 2024: $2.75 Million USD
Based on the latest financial reports, PaxMedica, Inc. Common Stock (PXMD) has total liabilities worth $2.75 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PaxMedica, Inc. Common Stock - Total Liabilities Trend (2018–2023)
This chart illustrates how PaxMedica, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PaxMedica, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of PaxMedica, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TetraLogic Pharmaceuticals Corp
PINK:TLOG
|
USA | $73.73 Million |
|
PRIMAG (P9R.SG)
STU:P9R
|
Germany | €2.12 Million |
|
ELEMENTOS (9EM.SG)
STU:9EM
|
Germany | €1.98 Million |
|
CANFOR PULP (8CP.SG)
STU:8CP
|
Germany | €297.20 Million |
|
Converge Information & Communications Technology Solutions Inc
PSE:CNVRG
|
Philippines | ₱60.49 Billion |
|
PEAK RES
BE:M3U
|
Germany | €2.60 Million |
|
GOAT Industries Ltd.
F:26B
|
Germany | €675.96K |
Liability Composition Analysis (2018–2023)
This chart breaks down PaxMedica, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PaxMedica, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PaxMedica, Inc. Common Stock (2018–2023)
The table below shows the annual total liabilities of PaxMedica, Inc. Common Stock from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $2.30 Million | +9.54% |
| 2022-12-31 | $2.10 Million | -80.52% |
| 2021-12-31 | $10.76 Million | +87.02% |
| 2020-12-31 | $5.75 Million | +4567.15% |
| 2019-12-31 | $123.25K | +1767.11% |
| 2018-12-31 | $6.60K | -- |